Page last updated: 2024-09-04

cyc 202 and tricalcium phosphate

cyc 202 has been researched along with tricalcium phosphate in 1 studies

Compound Research Comparison

Studies (cyc 202)	Trials (cyc 202)	Recent Studies (post-2010) (cyc 202)	Studies (tricalcium phosphate)	Trials (tricalcium phosphate)	Recent Studies (post-2010) (tricalcium phosphate)
979	7	393	14,239	521	5,961

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Elmslie, KS; Yarotskyy, V	1

Other Studies

1 other study(ies) available for cyc 202 and tricalcium phosphate

Article	Year
Roscovitine, a cyclin-dependent kinase inhibitor, affects several gating mechanisms to inhibit cardiac L-type (Ca(V)1.2) calcium channels. British journal of pharmacology, 2007, Volume: 152, Issue:3 Topics: Binding Sites; Calcium Channels, L-Type; Calcium Phosphates; Cardiovascular Diseases; Cell Line; Chemical Precipitation; Cyclin-Dependent Kinases; Electrophysiology; Humans; Ion Channel Gating; Patch-Clamp Techniques; Protein Kinase Inhibitors; Purines; Roscovitine; Transfection	2007

Article

Year

Roscovitine, a cyclin-dependent kinase inhibitor, affects several gating mechanisms to inhibit cardiac L-type (Ca(V)1.2) calcium channels.

British journal of pharmacology, 2007, Volume: 152, Issue:3

Topics: Binding Sites; Calcium Channels, L-Type; Calcium Phosphates; Cardiovascular Diseases; Cell Line; Chemical Precipitation; Cyclin-Dependent Kinases; Electrophysiology; Humans; Ion Channel Gating; Patch-Clamp Techniques; Protein Kinase Inhibitors; Purines; Roscovitine; Transfection

2007